Targeting TNF alpha as a novel strategy to enhance CD8+ T cell-dependent immune response in melanoma?

Florie Bertrand; Julia Rochotte; Céline Colacios; Anne Montfort; Nathalie Andrieu-Abadie; Thierry Levade; Hervé Benoist; Bruno Ségui

doi:10.1080/2162402X.2015.1068495

Targeting TNF alpha as a novel strategy to enhance CD8⁺ T cell-dependent immune response in melanoma?

Oncoimmunology. 2015 Aug 12;5(1):e1068495. doi: 10.1080/2162402X.2015.1068495. eCollection 2016.

Authors

Florie Bertrand¹, Julia Rochotte², Céline Colacios², Anne Montfort³, Nathalie Andrieu-Abadie¹, Thierry Levade², Hervé Benoist², Bruno Ségui²

Affiliations

¹ INSERM UMR 1037, CRCT, Toulouse, France; Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.
² INSERM UMR 1037, CRCT, Toulouse, France; Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France; Université Toulouse III - Paul Sabatier, Toulouse, France.
³ INSERM UMR 1037, CRCT, Toulouse, France; Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France; Present affiliation: Queen Mary University, London, UK.

Abstract

Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8⁺ T lymphocytes in experimental melanoma.

Keywords: Apoptosis; T lymphocytes; TNF; high endothelial venules; melanoma; tumor-infiltrating CD8+ lymphocytes.

Publication types

Research Support, Non-U.S. Gov't